DOCSLIB.ORG

CEDIA® Buprenorphine II Assay

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
CEDIA® Buprenorphine II Assay CEDIA® Buprenorphine II Assay For In Vitro Diagnostic Use Only Rx Only 10020849 (3 x 17 mL Kit) 10020850 (65 mL Kit) Intended Use Warnings and Precautions The CEDIA® Buprenorphine II Assay is a homogeneous enzyme immunoassay for the DANGER: Powder reagents contain ≤55% w/w Bovine Serum Albumin (BSA) fragments and qualitative and/or semi-quantitative determination for the presence of buprenorphine and its ≤1% w/w Sodium Azide. Liquid reagents contain ≤0.5% Bovine Serum, ≤0.2% Sodium Azide, metabolites in human urine at a cut-off concentration of 10 ng/mL. The assay is intended to and ≤0.1% Drug-Specific Antibody (Mouse). be used in laboratories and provides a simple and rapid analytical screening procedure to detect buprenorphine and its metabolites in human urine. The assay is designed for use with a The reagents are harmful if swallowed. number of clinical chemistry analyzers. H317 - May cause allergic skin reaction. The semi-quantitative mode is for the purpose of enabling laboratories to determine an H334 - May cause allergy or asthma symptoms or breathing difficulties if inhaled. appropriate dilution of the specimen for confirmation by a confirmatory method such as EUH032 - Contact with acids liberates very toxic gas. Liquid chromatography/tandem mass spectrometry (LC-MS/MS) or permitting laboratories to establish quality control procedures. Avoid breathing mist or vapor. Contaminated work clothing should not be allowed out of the workplace. Wear protective gloves/eye protection/face protection. In case of inadequate The assay provides only a preliminary analytical test result. A more specific alternative ventilation wear respiratory protection. If on skin: Wash with plenty of soap and water. IF chemical method must be used to obtain a confirmed analytical result. Gas chromatography/ INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position mass spectrometry (GC/MS) or Liquid chromatography/tandem mass spectrometry comfortable for breathing. If skin irritation or rash occurs: Get medical advice/attention. (LC-MS/MS) is the preferred confirmatory method.1 If experiencing respiratory symptoms: Call a POISON CENTER or a doctor/physician. Wash contaminated clothing before reuse. Dispose of contents/container to location in accordance Clinical and professional judgment should be applied to any drugs of abuse test result, with local/regional/national/international regulations. particularly when preliminary results are used. For In Vitro Diagnostic Use Only. In the case of accidental spill, clean and dispose of material according to your laboratory’s Summary and Explanation of the Test Standard Operating Procedure (SOP), local, and state regulations. Buprenorphine is a semi-synthetic opioid analgesic derived from thebaine, a minor component of opium. Buprenorphine is structurally similar to morphine. It is a partial agonist receptor In the case of damaged packaging on arrival, contact your technical support representative modulator.2 Buprenorphine has a longer duration of action than morphine and can be (refer to last page of this Package Insert). administered sublingually as an analgesic. Subutex®, a higher dose buprenorphine formulation, is widely used in Europe and elsewhere as a substitution treatment for opiate addiction.3-5 Reagent Preparation and Storage The FDA has approved the use of Subutex and Suboxone®, containing buprenorphine as the For preparation of the solutions, refer to the section below. Remove the kit from refrigerated active drug, for the treatment of opiate dependence in the US. Subutex and Suboxone are storage (2-8°C) immediately prior to preparation of the solutions. the first narcotic drugs available under the US Drug Abuse Treatment Act (DATA) of 2003 for the treatment of opiate dependence that can be prescribed in the US in a physician’s work Prepare the solutions in the following order to minimize possible contamination. place.6 It has also been shown that buprenorphine has abuse potential and may cause dependency. In addition, a number of deaths have been recorded as a result of overdose R2 Enzyme Donor Solution with intravenously injected buprenorphine in conjunction with other psychotropic drugs Connect Bottle 2a (ED reagent) to Bottle 2 (ED Reconstitution Buffer) using one of the enclosed such as benzodiazepines.7 Buprenorphine is metabolized primarily by N-dealkylation to form adapters. Mix by gentle inversion, ensuring that all the lyophilized material from Bottle 2a norbuprenorphine and by conjugation to form buprenorphine-glucuronide and is transferred into Bottle 2. Avoid the formation of foam. Detach Bottle 2a and adapter from norbuprenorphine-glucuronide.8 Bottle 2 and discard. Cap Bottle 2 and let stand approximately 5 minutes at room temperature (21-25°C). Mix again. Record the reconstitution date on the bottle label. Place the bottle The CEDIA Buprenorphine II Assay uses recombinant DNA technology to produce a directly into the reagent compartment of the analyzer or into refrigerated storage (2-8°C) and 9 unique homogeneous enzyme immunoassay system. The assay is based on the bacterial let stand 30 minutes before use. β-galactosidase enzyme (Escherichia coli), which has been genetically engineered into two inactive fragments. These fragments spontaneously re-associate to form fully active enzymes R1 Enzyme Acceptor Solution that, in the assay format, cleave a substrate, generating a color change that can be measured Connect Bottle 1a (EA reagent) to Bottle 1 (EA Reconstitution Buffer) using one of the enclosed spectrophotometrically at 570 nm. adapters. Mix by gentle inversion, ensuring that all the lyophilized material from Bottle 1a is transferred into Bottle 1. Avoid the formation of foam. Detach Bottle 1a and adapter from In this assay, the analyte in the sample competes with the analyte conjugated to the inactive Bottle 1 and discard. Cap Bottle 1 and let stand approximately 5 minutes at room temperature fragment (enzyme donor) of the β-galactosidase enzyme for the antibody binding site. If the (21-25°C). Mix again. Record the reconstitution date on the bottle label. Place the bottle analyte is present in the sample, it binds to the antibody, leaving the inactive enzyme fragment directly into the reagent compartment of the analyzer or into refrigerated storage (2-8°C) and free to form active enzyme. If the analyte is not present in the sample, antibody binds to let stand 30 minutes before use. the analyte conjugated on the inactive fragment, inhibiting the re-association of inactive -galactosidase fragments, and no active enzyme is formed. The amount of active enzyme β NOTE 1: The components supplied in this kit are intended for use as an integral unit. Do formed and resultant absorbance change is directly proportional to the amount of analyte not mix components from different lots. present in the sample. Reagents NOTE 2: Avoid cross-contamination of reagents by matching reagent caps to the proper reagent bottles. The R2 solution (Enzyme Donor) should be yellow-orange in color. A red or red- 1 EA Reconstitution Buffer purple color indicates that the reagent has been contaminated and must be discarded. Discard Contains buffer salts, mouse monoclonal anti-buprenorphine derivative antibody Reagents 1 or 2 if turbidity or precipitates are observed. 0.8 - 1.0 mg/L, stabilizer, and preservative. 1a EA Reagent Contains 0.171 g/L Enzyme Acceptor, buffer salts and preservative. NOTE 3: The R1 and R2 solutions must be at the reagent compartment storage temperature 2 ED Reconstitution Buffer of the analyzer before performing the assay. Refer to the analyzer specific application sheet Contains buffer salts, stabilizers, and preservatives for additional information. 2a ED Reagent Store reagents at 2-8°C. DO NOT FREEZE. Contains 0.175 mg/L Enzyme Donor conjugated to buprenorphine derivative, 1.67 g/L chlorophenol red-β-D-galactopyranoside, stabilizers, detergent and preservative. For shelf life of the unopened components, refer to the box or bottle labels for the expiration date. Additional Materials Required (sold separately): R1 Solution: 60 days refrigerated on analyzer or at 2-8°C. Kit Description R2 Solution: 60 days refrigerated on analyzer or at 2-8°C. 10021390 CEDIA Negative Calibrator II (1 x 7.5 mL) 10020799 CEDIA Buprenorphine II Calibrator 10 ng/mL (1 x 5 mL) 10020800 CEDIA Buprenorphine II Calibrator 20 ng/mL (1 x 5 mL) 10020801 CEDIA Buprenorphine II Calibrator 50 ng/mL (1 x 5 mL) 10020802 CEDIA Buprenorphine II Calibrator 100 ng/mL (1 x 5 mL) 10020804 CEDIA Buprenorphine II Low (7.5 ng/mL) and High (12.5 ng/mL) Controls (2 x 5 mL each) Specimen Collection and Handling Qualitative Study Analysis Collect urine specimens in plastic or glass containers. Care should be taken to preserve the Total Precision (n=80) chemical integrity of the urine sample from the time it is collected until the time it is assayed. Buprenorphine Spike % of Cutoff LC-MS/MS Immunoassay Number of Specimens kept at room temperature that do not receive initial test within 8 days10 of arrival at Concentration (10 ng/mL) (ng/mL) Results Determinations the laboratory should be placed into a secure refrigeration unit at 2-8°C for up to 30 days.11,12 (ng/mL) (Negative/Positive) For longer storage prior to analysis or for sample retention after analysis, urine specimens 0 -100% 0.00 80 80/0 may be stored at -20°C.13 Studies have shown buprenorphine analytes in urine are stable at -20°C up to 85 days.13 2.5 -75% 2.99 80 80/0 Laboratories following the SAMHSA mandatory guidelines should refer to SAMHSA “Short- 5 -50% 5.31 80 80/0 Term Refrigerated Storage” and “Long-Term Storage” requirements.14 7.5 -25% 7.63 80 80/0 To protect the integrity of the sample, do not induce foaming and avoid repeated freezing 10 100% 10.99 80 27/53 and thawing. An effort should be made to keep pipetted samples free of gross debris.
Load more

Recommended publications
  • An Examination of the Complex Pharmacological Properties of the Non-Selective Opioid Receptor Modulator Buprenorphine Leana J. P
    Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 17 November 2020 doi:10.20944/preprints202011.0443.v1 An Examination of the Complex Pharmacological Properties of the Non-Selective Opioid Receptor Modulator Buprenorphine Leana J. Pande1, Brian J. Piper1,2* 1Department of Medical Education, Geisinger Commonwealth School of Medicine 2Center for Pharmacy Innovation and Outcomes * Brian J. Piper, Ph.D.525 Pine Street, Geisinger Commonwealth School of Medicine Scranton, PA 18411, USA Abstract: Buprenorphine, an analogue of thebaine, is a Schedule III opioid in the United States used for opioid-use disorder and as an analgesic. Research has shown drugs like buprenorphine have a complicated pharmacology with characteristics that challenge traditional definitions of terms like agonist, antagonist, and efficacy. Buprenorphine has a high affinity for the mu (MOR), delta (DOR), kappa (KOR), and intermediate for the nociceptin opioid receptors (NOR). Buprenorphine is generally described as a partial MOR agonist with limited activity and decreased response at the mu- receptor relative to full agonists. In opioid naïve patients, the drug’s analgesic efficacy is equivalent to a full MOR agonist, despite decreased receptor occupancy and the “ceiling effect” produced from larger doses. Some argue buprenorphine’s effects depend on the endpoint measured, as it functions as a partial agonist for respiratory depression, but a full-agonist for pain. Buprenorphine’s active metabolite, norbuprenorphine, attenuates buprenorphine's analgesic effects due to NOR binding and respiratory depressant effects. The method of administration impacts efficacy and tolerance when administered for analgesia. There have been eleven-thousand reports involving buprenorphine and minors (age < 19) to US poison control centers, the preponderance (89.2%) with children.
    [Show full text]
  • Guidelines for the Forensic Analysis of Drugs Facilitating Sexual Assault and Other Criminal Acts
    Vienna International Centre, PO Box 500, 1400 Vienna, Austria Tel.: (+43-1) 26060-0, Fax: (+43-1) 26060-5866, www.unodc.org Guidelines for the Forensic analysis of drugs facilitating sexual assault and other criminal acts United Nations publication Printed in Austria ST/NAR/45 *1186331*V.11-86331—December 2011 —300 Photo credits: UNODC Photo Library, iStock.com/Abel Mitja Varela Laboratory and Scientific Section UNITED NATIONS OFFICE ON DRUGS AND CRIME Vienna Guidelines for the forensic analysis of drugs facilitating sexual assault and other criminal acts UNITED NATIONS New York, 2011 ST/NAR/45 © United Nations, December 2011. All rights reserved. The designations employed and the presentation of material in this publication do not imply the expression of any opinion whatsoever on the part of the Secretariat of the United Nations concerning the legal status of any country, territory, city or area, or of its authorities, or concerning the delimitation of its frontiers or boundaries. This publication has not been formally edited. Publishing production: English, Publishing and Library Section, United Nations Office at Vienna. List of abbreviations . v Acknowledgements .......................................... vii 1. Introduction............................................. 1 1.1. Background ........................................ 1 1.2. Purpose and scope of the manual ...................... 2 2. Investigative and analytical challenges ....................... 5 3 Evidence collection ...................................... 9 3.1. Evidence collection kits .............................. 9 3.2. Sample transfer and storage........................... 10 3.3. Biological samples and sampling ...................... 11 3.4. Other samples ...................................... 12 4. Analytical considerations .................................. 13 4.1. Substances encountered in DFSA and other DFC cases .... 13 4.2. Procedures and analytical strategy...................... 14 4.3. Analytical methodology .............................. 15 4.4.
    [Show full text]
  • Development of Pain-Free Methods for Analyzing 231 Multiclass Drugs and Metabolites by LC-MS/MS
    Clinical, Forensic & Toxicology Article “The Big Pain”: Development of Pain-Free Methods for Analyzing 231 Multiclass Drugs and Metabolites by LC-MS/MS By Sharon Lupo As the use of prescription and nonprescription drugs grows, the need for fast, accurate, and comprehensive methods is also rapidly increasing. Historically, drug testing has focused on forensic applications such as cause of death determinations or the detection of drug use in specific populations (military, workplace, probation/parole, sports doping). However, modern drug testing has expanded well into the clinical arena with a growing list of target analytes and testing purposes. Clinicians often request the analysis of large panels of drugs and metabolites that can be used to ensure compliance with prescribed pain medication regimens and to detect abuse or diversion of medications. With prescription drug abuse reaching epidemic levels [1], demand is growing for analytical methods that can ensure accurate results for comprehensive drug lists with reasonable analysis times. LC-MS/MS is an excellent technique for this work because it offers greater sensitivity and specificity than immunoassay and—with a highly selective and retentive Raptor™ Biphenyl column—can provide definitive results for a wide range of compounds. Typically, forensic and pain management drug testing consists of an initial screening analysis, which is qualitative, quick, and requires only minimal sample preparation. Samples that test positive during screening are then subjected to a quantitative confirmatory analysis. Whereas screening assays may cover a broad list of compounds and are generally less sensitive and specific, confirmation testing provides fast, targeted analysis using chromatographic conditions that are optimized for specific panels.
    [Show full text]
  • Use of Analgesics in Exotic Felids Edward C. Ramsay, DVM Professor, Department of Small Animal Clinical Sciences, University Of
    Use of Analgesics in Exotic Felids Formatted: Centered Edward C. Ramsay, DVM Professor, Department of Small Animal Clinical Sciences, University of Tennessee, and Consulting Veterinarian, Knoxville Zoological Gardens, Knoxville, Tennessee. Corresponding address: Ed Ramsay Dept. of Sm Animal Clin Sci C247, Veterinary Teaching Hospital University of Tennessee Knoxville, TN 37996-4544 Phone: 865-755-8219 FAX: 865-974-5554 Email: [email protected] 2 Treatment of pain in domestic and non-domestic cats has been a challenge for the clinician. Many cat species are stoic and show few or very subtle external signs of pain. Additionally, the adverse effects of nonsteroidal antiinflammatory drugs (NSAIDs) in domestic cats are well documented and have discouraged many practitioners from trying novel NSAID’s in exotic felids. As in other animals, each cat’s response to pain and analgesics will vary, necessitating an individualized treatment plan. As a rule, always treat painful felids to effect, and not by rote reliance on published dosages. It is frequently necessary to try different agents and combinations to find which produces the optimal analgesic effect in exotic felids. In order to minimize adverse effects, it is desirable to work toward treatment with the lowest effective dose when treating chronic pain. Non-steroidal Antiinflammatory Drugs NSAIDs are antiinflammatory drugs which act both centrally and peripherally. The primary effects are believed to be caused by their ability to inhibit cyclooxygenase (COX) enzymes in the arachidonic acid metabolism cascade. The COX-1 isoform is regarded as constitutive (continuously expressed) and is responsible for many homeostatic processes, such as maintenance of gastric mucosal integrity, platelet function, and renal autoregulation.
    [Show full text]
  • Big Pain Assays Aren't a Big Pain with the Raptor Biphenyl LC Column
    Featured Application: 231 Pain Management and Drugs of Abuse Compounds in under 10 Minutes by LC-MS/MS Big Pain Assays Aren’t a Big Pain with the Raptor Biphenyl LC Column • 231 compounds, 40+ isobars, 10 drug classes, 22 ESI- compounds in 10 minutes with 1 column. • A Raptor SPP LC column with time-tested Restek Biphenyl selectivity is the most versatile, multiclass-capable LC column available. • Achieve excellent separation of critical isobars with no tailing peaks. • Run fast and reliable high-throughput LC-MS/MS analyses with increased sensitivity using simple mobile phases. The use of pain management drugs is steadily increasing. As a result, hospital and reference labs are seeing an increase in patient samples that must be screened for a wide variety of pain management drugs to prevent drug abuse and to ensure patient safety and adherence to their medication regimen. Thera- peutic drug monitoring can be challenging due to the low cutoff levels, potential matrix interferences, and isobaric drug compounds. To address these chal- lenges, many drug testing facilities are turning to liquid chromatography coupled with mass spectrometry (LC-MS/MS) for its increased speed, sensitivity, and specificity. As shown in the analysis below, Restek’s Raptor Biphenyl column is ideal for developing successful LC-MS/MS pain medication screening methodologies. With its exceptionally high retention and unique selectivity, 231 multiclass drug compounds and metabolites—including over 40 isobars—can be analyzed in just 10 minutes. In addition, separate panels have been optimized on the Raptor Biphenyl column specifically for opioids, antianxiety drugs, barbiturates, NSAIDs and analgesics, antidepressants, antiepileptics, antipsychotics, hallucinogens, and stimulants for use during confirmation and quantitative analyses.
    [Show full text]
  • LZI Buprenorphine Enzyme Immunoassay for in Vitro Diagnostic Use Only 8ºC 0270 (100/37.5 Ml R1/R2 Kit) 0271 (1000/375 Ml R1/R2 Kit) 2ºC
    LZI Buprenorphine Enzyme Immunoassay For In Vitro Diagnostic Use Only 8ºC 0270 (100/37.5 mL R1/R2 Kit) 0271 (1000/375 mL R1/R2 Kit) 2ºC Lin-Zhi International, Inc. Intended Use Calibrators and Controls* The Lin-Zhi International (LZI) Buprenorphine Enzyme Immunoassay is *Calibrators and controls are sold separately and contain negative human intended for the qualitative and semi-quantitative determination of urine with sodium azide as a preservative. norbuprenorphine (a buprenorphine metabolite) in human urine at a cutoff value NORBUPRENORPHINE Calibrators/Controls REF of 5 ng/mL and 10 ng/mL. The assay is designed for prescription use with a Negative Calibrator 0001 number of automated clinical chemistry analyzers. Control: Contains 3 ng/mL norbuprenorphine 0272 The assay provides only a preliminary analytical result. A more specific Cutoff/Calibrator: Contains 5 ng/mL norbuprenorphine 0273 alternative analytical chemistry method must be used in order to obtain a Control: Contains 7 ng/mL norbuprenorphine 0274 confirmed analytical result. Gas or Liquid Chromatography/Mass Cutoff/Calibrator: Contains 10 ng/mL norbuprenorphine 0275 Control: Contains 13 ng/mL norbuprenorphine 0276 Spectrometry (GC/MS or LC/MS) are the preferred confirmatory methods Calibrator: Contains 20 ng/mL norbuprenorphine 0277 (1, 2). Clinical consideration and professional judgment should be exercised Calibrator: Contains 40 ng/mL norbuprenorphine 0278 with any drug of abuse test result, particularly when the preliminary test Calibrator: Contains 75 ng/mL norbuprenorphine 0279 result is positive. Precautions and Warning Summary and Explanation of Test • This test is for in vitro diagnostic use only. Harmful if swallowed. Buprenorphine is a semi-synthetic opioid derived from thebaine, an alkaloid of • Reagents used in the assay contain sodium azide as a preservative, which the poppy plant, Papaver somniferum.
    [Show full text]
  • A Generic LC-MS Method for the Analysis of Multiple of Drug of Abuse Classes with the Thermo Scientific Exactive TM System
    A Generic LC-MS Method for the Analysis of Multiple of Drug of Abuse Classes with the Thermo Scientific Exactive TM System Kent Johnson Fortes lab, Wilsonville Oregon Forensic Toxicology Use Only List of drug of abuse candidates for LC-MS analysis Sample matrix: urine and blood Benzodiazepines Opiates Other drugs group 1 Other drugs group 2 7-Aminonitrazepam Morphine Ketamine Methylphenidate 7-Aminoclonazepam Hydromorphone Norketamine Ritalinic Acid 7-Aminoflunitrazepam Oxymorphone Butorphanol Dextromethorphan 2-Hydroxy-ethyl-flurazepam Codeine Fentanyl Dextrophan Desalkylflurazepam Dihydrocodeine Norfentanyl Propoxyphene Diazepam Hydrocodone Nalbuphine Norpropoxyphene Hydroxy-alprazolam Oxycodone Alfentanil 6-MAM Hydroxy-triazolam Meperidine Sulfentanil Nordiazepam Normeperidine Zolpidem Lorazepam Trazodone Oxazepam Venlafaxine Temazepam Zopiclone Forensic Toxicology Use Only 2 Methods Employed Prior to LC-MS • Benzodiazepines GC-MS • Opiates GC-MS • Other drugs of abuse group 1 ELISA • Other drugs of abuse group 2 not analyzed before Forensic Toxicology Use Only 3 Why switch to LC-MS method? Benefits of replacing GC-MS • Faster less need for chromatographic separation • Less sample prep no derivatization • No thermal instability benzodiazepines analysis • No volatility limitations Benefits of replacing immunoassay • Lower consumables cost • More specific More cost efficient and analytically more universal Forensic Toxicology Use Only 4 Goal • Develop fast, easy to use, generic LC-MS method to analyze multiple classes of drugs
    [Show full text]
  • Integrating Buprenorphine Treatment for Opioid Use Disorder in HIV Primary Care
    Integrating Buprenorphine Treatment for Opioid Use Disorder in HIV Primary Care Michael MacVeigh, MD K r i st en Meyer s, BS, C A D C 1 May 10-12, 2017 Por t land Our Clinic Building Overview • W elcome Back and Overview of Bup TA training • Sit e Specific Updat es • Opioid Crisis: Nationwide Overview • Stigma, Shame, and the Power of Language • Relapse Sensitive Environments and Retention in Care • Met hods t o Reduce Diversion • Higher Level of Care, Alt ernat ives t o OBOT, Tapering Off Bup • Mental Health and OUD • Pain and OUD Metro Health Clinic Bluegrass Care Clinic Centro Ararat Clinic Opioid Crisis Nationwide Nationally, opioids were involved in more than 61 percent of deaths from overdoses in 2014 By HAEYOUN PARK and MATTHEW BLOCH JAN. 19, 2016, New York Times The C.D.C. says that 91 people in the United States die every day from opioid overdose. By CHRISTINE HAUSERFEB. 13, 2017, New York Times 2015 Data Comparison Overdose deaths: 52,404. Car crashes deaths: 37,757 Gun deaths, including homicides and suicides: 36,252 NBC News, Dec 9 2016 N gggg 2016 National Drug Threat Summary Opiate Crisis Nationwide “Deaths from overdoses are reaching levels similar to the H.I.V. epidemic at its peak” Robert Anderson, the C.D.C.’s chief of mortality statistics. HIV and OUD: ?W h o ? W h a t ? a r e w e t r e a t i n g ? 29 year old m ale 1/18/2017: HIV Viral Load= <20 1/25/2016: Pain MGMT Profile: +Amphetamines +Methamphetamines +Benzodiazepines +Mar ijuana +Opiat es +Morphine HIV and OUD 32 year old m ale 11/15/2016: HIV Viral Load= 26 2/19/2017:
    [Show full text]
  • Fatal Toxicity of Antidepressant Drugs in Overdose
    BRITISH MEDICAL JOURNAL VOLUME 295 24 OCTOBER 1987 1021 Br Med J (Clin Res Ed): first published as 10.1136/bmj.295.6605.1021 on 24 October 1987. Downloaded from PAPERS AND SHORT REPORTS Fatal toxicity of antidepressant drugs in overdose SIMON CASSIDY, JOHN HENRY Abstract dangerous in overdose, thus meriting investigation of their toxic properties and closer consideration of the circumstances in which A fatal toxicity index (deaths per million National Health Service they are prescribed. Recommendations may thus be made that prescriptions) was calculated for antidepressant drugs on sale might reduce the number offatalities. during the years 1975-84 in England, Wales, and Scotland. The We used national mortality statistics and prescription data tricyclic drugs introduced before 1970 had a higher index than the to compile fatal toxicity indices for the currently available anti- mean for all the drugs studied (p<0-001). In this group the depressant drugs to assess the comparative safety of the different toxicity ofamitriptyline, dibenzepin, desipramine, and dothiepin antidepressant drugs from an epidemiological standpoint. Owing to was significantly higher, while that ofclomipramine, imipramine, the nature of the disease these drugs are particularly likely to be iprindole, protriptyline, and trimipramine was lower. The mono- taken in overdose and often cause death. amine oxidase inhibitors had intermediate toxicity, and the antidepressants introduced since 1973, considered as a group, had significantly lower toxicity than the mean (p<0-001). Ofthese newer drugs, maprotiline had a fatal toxicity index similar to that Sources ofinformation and methods of the older tricyclic antidepressants, while the other newly The statistical sources used list drugs under their generic and proprietary http://www.bmj.com/ introduced drugs had lower toxicity indices, with those for names.
    [Show full text]
  • Drug-Facilitated Sexual Assault Panel, Blood
    DRUG-FACILITATED SEXUAL ASSAULT PANEL, BLOOD Blood Specimens (Order Code 70500) Alcohols Analgesics, cont. Anticonvulsants, cont. Antihistamines, cont. Ethanol Phenylbutazone Phenytoin Cyclizine Amphetamines Piroxicam Pregabalin Diphenhydramine Amphetamine Salicylic Acid* Primidone Doxylamine BDB Sulindac* Topiramate Fexofenadine Benzphetamine Tapentadol Zonisamide Guaifenesin Ephedrine Tizanidine Antidepressants Hydroxyzine MDA Tolmetin Amitriptyline Loratadine MDMA Tramadol Amoxapine Oxymetazoline* Mescaline* Anesthetics Bupropion Pyrilamine Methcathinone Benzocaine Citalopram Tetrahydrozoline Methamphetamine Bupivacaine Clomipramine Triprolidine Phentermine Etomidate Desipramine Antipsychotics PMA Ketamine Desmethylclomipramine 9-hydroxyrisperidone Phenylpropanolamine Lidocaine Dosulepin Aripiprazole Pseudoephedrine Mepivacaine Doxepin Buspirone Analgesics Methoxetamine Duloxetine Chlorpromazine Acetaminophen Midazolam Fluoxetine Clozapine Baclofen Norketamine Fluvoxamine Fluphenazine Buprenorphine Pramoxine* Imipramine Haloperidol Carisoprodol Procaine 1,3-chlorophenylpiperazine (mCPP) Mesoridazine Cyclobenzaprine Rocuronium Mianserin* Norclozapine Diclofenac Ropivacaine Mirtazapine Olanzapine Etodolac Antibiotics Nefazodone Perphenazine Fenoprofen Azithromycin* Nordoxepin Pimozide Hydroxychloroquine Chloramphenicol* Norfluoxetine Prochlorperazine Ibuprofen Ciprofloxacin* Norsertraline Quetiapine Ketoprofen Clindamycin* Nortriptyline Risperidone Ketorolac Erythromycin* Norvenlafaxine Thioridazine Meclofenamic Acid* Levofloxacin* Paroxetine
    [Show full text]
  • Buprenorphine
    Buprenorphine: Everything You Need to Know OCTOBER 2016 uprenorphine, a medication that is FDA-approved others are FDA-approved for pain (injectable, patch, and for addiction treatment and pain relief, has also buccal mucoadhesive film). Bbeen found to dramatically decrease death rates from opioid overdose. Only 10% of patients needing Per the Drug Addiction Treatment Act of 2000 (DATA treatment, however, have access to the medication. 2000), physicians need a waiver to prescribe buprenor- phine for addiction; attendance in an eight-hour This document provides answers to frequently asked in-person or online course is required to obtain a waiver. questions about buprenorphine and supplements the The Comprehensive Addiction and Recovery Act of 2016 California Health Care Foundation (CHCF) webinars allows nurse practitioners and physician assistants to pre- “Expanding Access to Buprenorphine in Primary scribe buprenorphine treatment after 24 hours of certified Care Practices” and “Is Buprenorphine for Pain a training. Clinicians are capped at 30 patients the first year Safer Alternative to High-Dose or Long-Term Opioid and 100 patients per year thereafter. The cap increases Use?”1, 2 The clinical information contained in this paper to 275 patients for physicians board-certified in addic- is intended to act as a guideline, not a replacement for tion, or those in practices that meet certain qualifications: onsite medical judgment. Based on information cov- 24-hour call coverage, use of health information technol- ered in the CHCF webinars, the content was reviewed ogy, provision of care management services, registration by addiction specialists Howard Kornfeld, MD, James with CURES (Controlled Substance Utilization Review and Gasper, PharmD, and Andrew Herring, MD.
    [Show full text]
  • Chapter 329 [New] Uniform Controlled Substances Act
    CHAPTER 329 [NEW] UNIFORM CONTROLLED SUBSTANCES ACT Part I. General Provisions Section 329-1 Definitions 329-2 Hawaii advisory commission on drug abuse and controlled substances; number; appointment 329-3 Annual report 329-4 Duties of the commission Part II. Standards and Schedules 329-11 Authority to schedule controlled substances 329-12 Nomenclature 329-13 Schedule I tests 329-14 Schedule I 329-15 Schedule II tests 329-16 Schedule II 329-17 Schedule III Tests 329-18 Schedule III 329-19 Schedule IV tests 329-20 Schedule IV 329-21 Schedule V tests 329-22 Schedule V 329-23 Republishing and distribution of schedules Part III. Regulation of Manufacture, Distribution, Prescription, and Dispensing of Controlled Substances 329-31 Rules 329-31.5 Clinics 329-32 Registration requirements 329-33 Registration 329-34 Revocation and suspension of registration 329-35 Order to show cause 329-36 Records of registrants 329-37 Filing requirements 329-38 Prescriptions 329-39 Labels 329-40 Methadone treatment programs Part IV. Offenses and Penalties 329-41 Prohibited acts B-penalties 329-42 Prohibited acts C-penalties 329-43 Penalties under other laws 329-43.5 Prohibited acts related to drug paraphernalia Amended 0612 1 329-44 Notice of conviction to be sent to licensing board, department of commerce and consumer affairs 329-45 Repealed 329-46 Prohibited acts related to visits to more than one practitioner to obtain controlled substance prescriptions 329-49 Administrative penalties 329-50 Injunctive relief Part V. Enforcement and Administrative Provisions 329-51 Powers of enforcement personnel 329-52 Administrative inspections 329-53 Injunctions 329-54 Cooperative arrangements and confidentiality 329-55 Forfeitures 329-56 Burden of proof; liabilities 329-57 Judicial review 329-58 Education and research 329-59 Controlled substance registration revolving fund; established Part VI.
    [Show full text]